# Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

> **NCT00265434** · PHASE3 · COMPLETED · sponsor: **University of Jena** · enrollment: 5 (actual)

## Conditions studied

- Cystic Fibrosis
- Chronic Rhinosinusitis

## Interventions

- **DRUG:** Pulmozyme

## Key facts

- **NCT ID:** NCT00265434
- **Lead sponsor:** University of Jena
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2014-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265434, "Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00265434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*